323 related articles for article (PubMed ID: 34002252)
1. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05.
Hagino H; Sugimoto T; Tanaka S; Sasaki K; Sone T; Nakamura T; Soen S; Mori S
Osteoporos Int; 2021 Nov; 32(11):2301-2311. PubMed ID: 34002252
[TBL] [Abstract][Full Text] [Related]
2. Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.
Mori S; Hagino H; Sugimoto T; Tanaka S; Mitomo Y; Takahashi K; Sone T; Nakamura T; Soen S
Osteoporos Int; 2023 Jan; 34(1):189-199. PubMed ID: 36239756
[TBL] [Abstract][Full Text] [Related]
3. Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
Tanaka S; Mori S; Hagino H; Sugimoto T
J Bone Miner Metab; 2020 May; 38(3):412-417. PubMed ID: 31894491
[TBL] [Abstract][Full Text] [Related]
4. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
[TBL] [Abstract][Full Text] [Related]
5. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan.
Mori T; Crandall CJ; Fujii T; Ganz DA
Arch Osteoporos; 2021 Apr; 16(1):72. PubMed ID: 33866457
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
8. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
[TBL] [Abstract][Full Text] [Related]
9. Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
Hagino H; Tanaka S; Kuroda T; Mori S; Soen S
J Bone Miner Metab; 2024 May; 42(3):382-388. PubMed ID: 38755328
[TBL] [Abstract][Full Text] [Related]
10. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.
Harvey NC; Kanis JA; Odén A; Burge RT; Mitlak BH; Johansson H; McCloskey EV
Osteoporos Int; 2015 Nov; 26(11):2677-84. PubMed ID: 26092063
[TBL] [Abstract][Full Text] [Related]
11. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Saag KG; Petersen J; Brandi ML; Karaplis AC; Lorentzon M; Thomas T; Maddox J; Fan M; Meisner PD; Grauer A
N Engl J Med; 2017 Oct; 377(15):1417-1427. PubMed ID: 28892457
[TBL] [Abstract][Full Text] [Related]
12. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Kendler DL; Marin F; Zerbini CAF; Russo LA; Greenspan SL; Zikan V; Bagur A; Malouf-Sierra J; Lakatos P; Fahrleitner-Pammer A; Lespessailles E; Minisola S; Body JJ; Geusens P; Möricke R; López-Romero P
Lancet; 2018 Jan; 391(10117):230-240. PubMed ID: 29129436
[TBL] [Abstract][Full Text] [Related]
13. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
14. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Albert SG; Reddy S
Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
[TBL] [Abstract][Full Text] [Related]
15. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
Leder BZ; Mitlak B; Hu MY; Hattersley G; Bockman RS
J Clin Endocrinol Metab; 2020 Mar; 105(3):938-43. PubMed ID: 31674644
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
Nakamura T; Fukunaga M; Nakano T; Kishimoto H; Ito M; Hagino H; Sone T; Taguchi A; Tanaka S; Ohashi M; Ota Y; Shiraki M
Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.
Harvey NC; Kanis JA; Odén A; Nakamura T; Shiraki M; Sugimoto T; Kuroda T; Johansson H; McCloskey EV
Osteoporos Int; 2015 Sep; 26(9):2347-53. PubMed ID: 26092062
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of anti-osteoporosis medications in preventing vertebral body fractures after balloon kyphoplasty.
Ueno M; Tajima Y; Ito S; Tsuji M; Toriumi E; Yoshii A; Otake N; Tanaka H
Arch Osteoporos; 2024 Mar; 19(1):19. PubMed ID: 38512565
[TBL] [Abstract][Full Text] [Related]
19. Reduced risk of back pain following teriparatide treatment: a meta-analysis.
Nevitt MC; Chen P; Dore RK; Reginster JY; Kiel DP; Zanchetta JR; Glass EV; Krege JH
Osteoporos Int; 2006 Feb; 17(2):273-80. PubMed ID: 16142502
[TBL] [Abstract][Full Text] [Related]
20. Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis.
Fujita T; Fukunaga M; Itabashi A; Tsutani K; Nakamura T
Calcif Tissue Int; 2014 Feb; 94(2):170-5. PubMed ID: 23963633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
